PolyPeptide Group AG Overview
Pro stress-test →PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves a fast-growing market with a broad portfolio offering products and services from pre-clinical through commercial stages, with large exposure to metabolic diseases including GLP-1.
Strategic Profile
Pro stress-test →Established in 1952, PolyPeptide operates a global network of six GMP-certified facilities in Europe, the U.S. and India. The company is positioned as a specialized player in the high-growth peptide therapeutics market, benefiting from strong demand trends in novel drug development, particularly in metabolic disease treatments like GLP-1 agonists.
Competitive Landscape
Pro stress-test →PolyPeptide competes in the specialized peptide CDMO segment alongside larger diversified CDMOs like Catalent and specialized players like Lonza. The company differentiates through focused expertise in peptide manufacturing and exposure to high-growth therapeutic areas, particularly metabolic diseases. Competition centers on manufacturing capacity, regulatory expertise, and ability to support drug development across clinical stages.
Industry Context
PolyPeptide Group AG operates in Pharmaceutical Contract Development & Manufacturing Organization (CDMO) - Peptide & Oligonucleotide Specialization.
Key facts
Founded: 1952 · Headquarters: Switzerland